The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Open accessAbstract
Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has been undergoing constant evolution. This is largely attributed to the viral polymerase that is intrinsically error prone and the selection pressures exerted by the host immune system. Several variants of concern harboring multiple mutations in the spike protein have emerged in the past year. The currently fast-spreading Omicron variant contains many more mutations compared with the previous variants, and most of these mutations are located around the receptor binding domain of the spike protein. 1 This would dramatically, although not completely, compromise the efficacy of the existing COVID-19 vaccines. 2 Nearly all the monoclonal antibodies developed for treating COVID-19 are directed to the spike protein to prevent virus entry into human cells. Thus, it is not surprising that most of these antibodies are not effective against the Omicron variant. 3 Prompted by the potentially devastating impact of this new variant, we evaluated the effectiveness of two clinically available direct-acting antiviral agents on the Omicron variant in relevant experimental models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Lamers, M. M., van der Vaart, J., Knoops, K., Riesebosch, S., Breugem, T. I., Mykytyn, A. Z., Beumer, J., Schipper, D., Bezstarosti, K., Koopman, C. D., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020105912 · Cited by 227
Self-citationWang, Y., Li, P., Solanki, K., Li, Y., Ma, Z., Peppelenbosch, M. P., Baig, M. S., & Pan, Q. (2021) · Virology · doi:10.1016/j.virol.2021.09.009 · Cited by 46
Self-citation
Cited by
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 589
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Arbel, R., Wolff Sagy, Y., Hoshen, M., Battat, E., Lavie, G., Sergienko, R., Friger, M., Waxman, J. G., Dagan, N., Balicer, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204919 · Cited by 356
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01586-0 · Cited by 299
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00507-2 · Cited by 269
Cats and SARS-CoV-2: A Scoping Review
Doliff, R., & Martens, P. (2022) · Animals · doi:10.3390/ani12111413 · Cited by 34
Metadata
- Authors
- Li, P., Wang, Y., Lavrijsen, M., Lamers, M. M., de Vries, A. C., Rottier, R. J., Bruno, M. J., Peppelenbosch, M. P., Haagmans, B. L., & Pan, Q.
- Venue
- Cell Research
- Published
- 2022-01-20
- Volume
- 32
- Issue
- 3
- Pages
- 322-324
- ISSN
- 1001-0602 (ISSN-L)
- 1748-7838
- OpenAlex
- W4205367704
- Cited by
- 181
- References
- 3
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. https://app.cochat.ai/papers/10.1038/s41422-022-00618-w
- The paper
- Li, P., Wang, Y., Lavrijsen, M., Lamers, M. M., de Vries, A. C., Rottier, R. J., Bruno, M. J., Peppelenbosch, M. P., Haagmans, B. L., & Pan, Q. (2022). SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research. https://doi.org/10.1038/s41422-022-00618-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.